{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T22:05:03Z","timestamp":1778882703885,"version":"3.51.4"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:p>Low-grade serous carcinoma (LGSC) is an uncommon histotype of ovarian carcinoma, accounting for ~3% of cases. There is evidence that survival of peritoneal LGSC (pLGSC) is longer than that of ovarian LGSC (oLGSC). Key molecular alterations of LGSC have been established, including loss of CDKN2A and PR expression, MAPK pathway alterations, and loss of USP9X expression. We hypothesized that LGSC could be subclassified into clinically applicable molecular subtypes by a few surrogate tests similar to endometrioid carcinomas using a hierarchical decision tree based on the strength of the prognostic associations of the individual alterations. Our study included 71 LGSCs. Immunohistochemistry for CDKN2A, ER, PR, NF1, and USP9X and sequencing for <jats:italic toggle=\"yes\">KRAS<\/jats:italic>, <jats:italic toggle=\"yes\">NRAS<\/jats:italic>, and <jats:italic toggle=\"yes\">BRAF<\/jats:italic> were performed. Our data showed the co-occurrence of key molecular alterations, and despite suggestive trends, hierarchical molecular subtyping did not provide significantly different stratification of patients according to survival in this cohort. We confirmed that patients diagnosed with pLGSC have a longer survival than high-stage oLGSC, with the intriguing observation that normal CDKN2A and PR status were associated with excellent survival in pLGSC. Therefore, CDKN2A and PR status might aid in the classification of indeterminate implants, where abnormal findings favor pLGSC over noninvasive implants. Molecular subtypes should be further evaluated in larger cohorts for their prognostic and potentially predictive value.<\/jats:p>","DOI":"10.1097\/pgp.0000000000001043","type":"journal-article","created":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T18:00:07Z","timestamp":1719252007000},"page":"617-625","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Molecular Surrogate Subtypes of Ovarian and Peritoneal Low-grade Serous Carcinoma"],"prefix":"10.1097","volume":"43","author":[{"given":"Annalyn","family":"Da-Anoy","sequence":"first","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of Calgary, Calgary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eun Young","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of Calgary, Calgary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng Han","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of Alberta, Edmonton, Alberta"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dane","family":"Cheasley","sequence":"additional","affiliation":[{"name":"Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, Melbourne"},{"name":"Sir Peter MacCallum Department of Oncology, University of Melbourne, VIC, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Llaurado Fernandez","sequence":"additional","affiliation":[{"name":"Department of Obstetrics & Gynecology, Faculty of Medicine, University of British Columbia, and the Department of Clinical Research, BC Cancer, Vancouver, BC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark S.","family":"Carey","sequence":"additional","affiliation":[{"name":"Department of Obstetrics & Gynecology, Faculty of Medicine, University of British Columbia, and the Department of Clinical Research, BC Cancer, Vancouver, BC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Cameron","sequence":"additional","affiliation":[{"name":"Department of Obstetrics & Gynecology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"K\u00f6bel","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of Calgary, Calgary"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,6,10]]},"reference":[{"key":"R1-20250802","first-page":"43","article-title":"Low-grade serous ovarian carcinoma: recommendation for efficient ancillary testing and standardized biomarker reporting from the Canadian LGSC community of practice","volume":"12","author":"Brett","year":"2020","journal-title":"Can J Pathology"},{"key":"R2-20250802","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1200\/JCO.2015.61.0873","article-title":"Impact of age and primary disease site on outcome in women with low-grade serous carcinoma of the ovary or peritoneum: results of a large single-institution registry of a rare tumor","volume":"33","author":"Gershenson","year":"2015","journal-title":"J Clin Oncol"},{"key":"R3-20250802","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ygyno.2020.01.021","article-title":"Low-grade serous carcinoma (LGSC): a Canadian multicenter review of practice patterns and patient outcomes","volume":"157","author":"Scott","year":"2020","journal-title":"Gynecol Oncol"},{"key":"R4-20250802","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/PGP.0000000000000613","article-title":"Low-grade serous carcinoma arising in inguinal nodal endosalpingiosis: report of 2 cases and literature review","volume":"39","author":"Sah","year":"2020","journal-title":"Int J Gynecol Pathol"},{"key":"R5-20250802","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/annonc\/mdz062","article-title":"ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease\u2020","volume":"30","author":"Colombo","year":"2019","journal-title":"Ann Oncol"},{"key":"R6-20250802","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1097\/PAS.0000000000000692","article-title":"Classification of extraovarian implants in patients with ovarian serous borderline tumors (tumors of low malignant potential) based on clinical outcome","volume":"40","author":"McKenney","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"R7-20250802","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41698-022-00288-2","article-title":"Molecular characterization of low-grade serous ovarian carcinoma identifies genomic aberrations according to hormone receptor expression","volume":"6","author":"Cheasley","year":"2022","journal-title":"NPJ precision oncology"},{"key":"R8-20250802","doi-asserted-by":"crossref","first-page":"4268","DOI":"10.1158\/0008-5472.CAN-16-2224","article-title":"EIF1AX and NRAS mutations co-occur and cooperate in low-grade serous ovarian carcinomas","volume":"77","author":"Etemadmoghadam","year":"2017","journal-title":"Cancer Res"},{"key":"R9-20250802","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/s41416-022-01897-1","article-title":"Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22)","volume":"127","author":"Musacchio","year":"2022","journal-title":"Br J Cancer"},{"key":"R10-20250802","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.ygyno.2022.09.022","article-title":"Genomic profiling in low grade serous ovarian cancer: identification of novel markers for disease diagnosis and therapy","volume":"167","author":"ElNaggar","year":"2022","journal-title":"Gynecol Oncol"},{"key":"R11-20250802","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1186\/s12967-022-03820-x","article-title":"Integrated multi-omic analysis of low-grade ovarian serous carcinoma collected from short and long-term survivors","volume":"20","author":"Wong","year":"2022","journal-title":"J Transl Med"},{"key":"R12-20250802","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.ygyno.2021.11.019","article-title":"The genomic landscape of low-grade serous ovarian\/peritoneal carcinoma and its impact on clinical outcomes","volume":"165","author":"Gershenson","year":"2022","journal-title":"Gynecol Oncol"},{"key":"R13-20250802","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ygyno.2023.04.011","article-title":"Whole exome sequencing of low grade serous ovarian carcinoma identifies genomic events associated with clinical outcome","volume":"174","author":"Thomson","year":"2023","journal-title":"Gynecol Oncol"},{"key":"R14-20250802","doi-asserted-by":"crossref","first-page":"7681","DOI":"10.1038\/s41598-023-34627-5","article-title":"Distinct histopathological features are associated with molecular subtypes and outcome in low grade serous ovarian carcinoma","volume":"13","author":"Hollis","year":"2023","journal-title":"Sci Rep"},{"key":"R15-20250802","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/path.5545","article-title":"Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities","volume":"253","author":"Cheasley","year":"2021","journal-title":"J Pathol"},{"key":"R16-20250802","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ygyno.2023.09.016","article-title":"Survey of NF1 inactivation by surrogate immunohistochemistry in ovarian carcinomas","volume":"178","author":"K\u00f6bel","year":"2023","journal-title":"Gynecol Oncol"},{"key":"R17-20250802","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/cjp2.109","article-title":"Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study","volume":"4","author":"Rambau","year":"2018","journal-title":"J Pathol Clin Res"},{"key":"R18-20250802","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1470-2045(13)70253-5","article-title":"Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study","volume":"14","author":"Sieh","year":"2013","journal-title":"Lancet Oncol"},{"key":"R19-20250802","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/bjc.2015.364","article-title":"Impact of mutational status on survival in low-grade serous carcinoma of the ovary or peritoneum","volume":"113","author":"Gershenson","year":"2015","journal-title":"Br J Cancer"},{"key":"R20-20250802","doi-asserted-by":"crossref","first-page":"5400","DOI":"10.1158\/1078-0432.CCR-20-1268","article-title":"Endometrial cancer molecular risk stratification is equally prognostic for endometrioid ovarian carcinoma","volume":"26","author":"Kr\u00e4mer","year":"2020","journal-title":"Clin Cancer Res"},{"key":"R21-20250802","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/his.13071","article-title":"Molecular alterations in indolent, aggressive and recurrent ovarian low-grade serous carcinoma","volume":"70","author":"McIntyre","year":"2017","journal-title":"Histopathology"},{"key":"R22-20250802","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/his.13796","article-title":"Somatic genetic alterations in synchronous and metachronous low-grade serous tumours and high-grade carcinomas of the adnexa","volume":"74","author":"Murali","year":"2019","journal-title":"Histopathology"},{"key":"R23-20250802","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/PGP.0000000000000725","article-title":"The many uses of p53 immunohistochemistry in gynecological pathology: proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual9 Meeting","volume":"40","author":"K\u00f6bel","year":"2021","journal-title":"Int J Gynecol Pathol"},{"key":"R24-20250802","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1097\/PAS.0000000000000693","article-title":"Low-grade serous carcinoma of the ovary: clinicopathologic analysis of 52 invasive cases and identification of a possible noninvasive intermediate lesion","volume":"40","author":"Ahn","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"R25-20250802","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1097\/PGP.0000000000000274","article-title":"An immunohistochemical algorithm for ovarian carcinoma typing","volume":"35","author":"K\u00f6bel","year":"2016","journal-title":"Int J Gynecol Pathol"},{"key":"R26-20250802","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/978-1-4939-6442-0_5","article-title":"The MassARRAY(\u00ae) System for Targeted SNP Genotyping","volume":"1492","author":"Ellis","year":"2017","journal-title":"Methods Mol Biol"},{"key":"R27-20250802","doi-asserted-by":"crossref","first-page":"416","DOI":"10.3390\/cancers14020416","article-title":"The evolution of ovarian carcinoma subclassification","volume":"14","author":"K\u00f6bel","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R28-20250802","doi-asserted-by":"crossref","first-page":"4456","DOI":"10.1158\/1078-0432.CCR-21-4183","article-title":"MAPK pathway genetic alterations are associated with prolonged overall survival in low-grade serous ovarian carcinoma","volume":"28","author":"Manning-Geist","year":"2022","journal-title":"Clin Cancer Res"},{"key":"R29-20250802","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.ygyno.2012.10.013","article-title":"Quantification of ER\/PR expression in ovarian low-grade serous carcinoma","volume":"128","author":"Escobar","year":"2013","journal-title":"Gynecol Oncol"},{"key":"R30-20250802","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ygyno.2019.11.029","article-title":"Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma","volume":"157","author":"Llaurado Fernandez","year":"2020","journal-title":"Gynecol Oncol"},{"key":"R31-20250802","doi-asserted-by":"crossref","first-page":"e232","DOI":"10.1371\/journal.pmed.0050232","article-title":"Ovarian carcinoma subtypes are different diseases: implications for biomarker studies","volume":"5","author":"K\u00f6bel","year":"2008","journal-title":"PLoS Med"},{"key":"R32-20250802","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1200\/JCO.2016.71.0632","article-title":"Hormonal maintenance therapy for women with low-grade serous cancer of the ovary or peritoneum","volume":"35","author":"Gershenson","year":"2017","journal-title":"J Clin Oncol"},{"key":"R33-20250802","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(21)02175-9","article-title":"Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281\/LOGS): an international, randomised, open-label, multicentre, phase 2\/3 trial","volume":"399","author":"Gershenson","year":"2022","journal-title":"Lancet"}],"container-title":["International Journal of Gynecological Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PGP.0000000000001043","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T19:01:04Z","timestamp":1754161264000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PGP.0000000000001043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,10]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/pgp.0000000000001043","relation":{},"ISSN":["0277-1691"],"issn-type":[{"value":"0277-1691","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,10]]}}}